Drug intelligence / Profile preview

carpatamides

Development stage: Preclinical
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

Carpatamides are a group of cytotoxic acylated arylamine derivatives (specifically, carpatamides A–C) isolated from a marine-derived Streptomyces species. These natural products feature a novel amide structure with an amino-phenylpropionic acid core and an unsaturated fatty acid chain. Carpatamides A and C have demonstrated moderate cytotoxicity against non-small-cell lung cancer (NSCLC) cell lines, with IC50 values ranging from 2.2 to 8.4 μM[1][2][6]. Their mechanism of action is not fully elucidated but they are notable for their unique chemical scaffold among marine natural products.

Other names: carpatamidescarpatamide Acarpatamide Bcarpatamide C

Beyond the preview

Go deeper on carpatamides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carpatamides.

Explore the full profile